APOE epsilon 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
Yen Ying Lim, Victor L Villemagne, Robert H Pietrzak, David Ames, Kathryn A Ellis, Karra Harrington, Peter J Snyder, Ralph N Martins, Colin L Masters, Christopher C Rowe, Paul Maruff
Neurobiology of Aging | ELSEVIER SCIENCE INC | Published : 2015
The apolipoprotein E (APOE) ɛ4 allele and high levels of beta-amyloid (Aβ) are associated with episodic memory decline and risk for Alzheimer's disease. However, there is debate about independent or interactive effects of ɛ4 on Aβ-related memory decline in healthy older adults. Healthy older adults with high Aβ burden (n = 84) enrolled in Australian Imaging, Biomarkers, and Lifestyle Study were included in this study. Cognition was measured using the computerized Cogstate Brief Battery at baseline, 18-, 36-, and 54-month follow-ups. Mini Mental State Examination and Clinical Dementia Rating scales were also administered at baseline and each follow-up timepoint. Relative to Aβ+ ɛ4 noncarriers..View full abstract
Funding for the study was provided in part by the study partners [Australian Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research Institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, CogState Ltd, Hollywood Private Hospital, and Sir Charles Gardner Hospital. The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as ongoing funding from the Science and Industry Endowment Fund (SIEF). The authors also acknowledge the financial support of the Cooperative Research Centre (CRC) for Mental Health, from the Australian Government.